SVRA Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Savara Inc.

SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Savara Inc. (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025. Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The Company’s lead product candidate is MOLBREEVI (also referred to as “molgramostim”), an inhaled granulocyte-macrophage colony-stimulating (“GM-CSF”) factor. For ...